Highlights

  • Medical Developments (ASX:MVP) returned to profitability in FY26 following improved operating performance.
  • Group Revenue increased 9% to A$42.6 million.
  • Penthrox revenue growth supported higher margins and positive cash flow.
  • Free Cash Flow reached A$4.2 million during FY26.

Medical Developments (ASX:MVP) reported improved FY26 performance, supported by growth in its Penthrox pain-management Business and a return to positive cash generation. The company’s shares were trading at AUD 0.48, unchanged on 21 August 2026.

The company’s FY26 results highlighted higher revenue, improved profitability and stronger cash flow, although performance remained dependent on continued growth from Penthrox and stabilisation of the respiratory segment.

For investors assessing Medical Developments (ASX:MVP), the key areas of focus remain Penthrox adoption, international expansion, cash flow sustainability and product concentration risk.

What is happening with Medical Developments?

Medical Developments is a healthcare company focused on pain management and respiratory products, with its flagship product being Penthrox, a methoxyflurane-based analgesic.

The company’s FY26 results showed progress following a period focused on restructuring, regulatory approvals and improving operating performance.

Penthrox remains the main contributor to Earnings growth, while the respiratory business continues undergoing a period of adjustment.

Latest company developments

Penthrox was the key driver of FY26 performance, with the pain-management segment generating revenue of A$31.6 million compared with A$26.2 million in the previous year.

Segment EBIT increased 49% to A$9.4 million.

The Australian business recorded revenue growth of 16% to A$17.9 million, supported by a 28% increase in hospital volumes and improved pricing.

European revenue reached A$9.0 million, supported by approximately 18% growth in in-market demand, while the rest-of-world segment contributed A$4.1 million.

The company also progressed regulatory and market expansion initiatives, including paediatric approval expansion for Penthrox in the UK and European markets for children aged six years and older.

The MAGPIE paediatric study was published during FY26, while expanded prescribing rights for nurse practitioners in Australia increased potential access channels.

The respiratory segment reported revenue of A$10.9 million, down 15%, although cost management supported a 63% increase in segment EBIT to A$0.7 million.

What do the numbers say?

Medical Developments reported FY26 group revenue of A$42.6 million, representing 9% growth.

Net profit after tax increased to A$0.6 million from A$0.1 million in the prior year, while EBIT improved to a A$0.2 million profit.

Cash generation was a key improvement, with free cash flow reaching A$4.2 million, an improvement of A$5.8 million compared with the previous year.

Operating cash flow was A$5.8 million, while Capital Expenditure was A$0.8 million.

The company ended FY26 with cash and short-term deposits of A$21.4 million.

The Penthrox segment’s contribution was significant, generating A$9.4 million in EBIT from A$31.6 million of revenue.

However, management noted that FY26 cash flow benefited partly from inventory-related factors that are not expected to repeat, while approximately A$1 million of European registration Amortisation is expected to affect future periods.

What could drive the shares from here?

Continued growth in Penthrox Demand remains the key potential driver for Medical Developments (ASX:MVP).

Further adoption across Australian hospitals, where volumes increased during FY26, could support ongoing revenue expansion.

Expansion of Penthrox eligibility through paediatric approvals in overseas markets provides additional growth opportunities.

Sustained European demand growth and potential new market approvals could further diversify revenue.

The ability to maintain positive free cash flow through FY27 will also be an important Factor for investor confidence.

Risks investors should watch

Product concentration remains a key risk, as Penthrox accounts for the majority of the company’s growth and profitability.

Any regulatory, competitive or reimbursement challenges affecting Penthrox could materially impact performance.

The respiratory segment continues facing pressure following lower revenue, which may offset some gains from pain management.

The company’s profitability remains relatively small compared with revenue, leaving limited room for unexpected cost increases or operational disruptions.

International operations also expose the company to currency movements, regulatory changes and market-specific risks.

Investor takeaway

Medical Developments (ASX:MVP) delivered a FY26 result showing improved operating performance, a return to profitability and positive free cash flow supported by Penthrox growth.

The company’s progress across Australian and European markets provides a foundation for future expansion, while the sustainability of cash generation and continued product adoption remain key considerations.

The factors to monitor include Penthrox demand, international growth, respiratory segment performance and whether positive cash flow can be maintained without relying on one-off benefits.